Biomarker analysis report

2017-08-29

Contents

1	The da	ataset	1
2	2.1 Cł 2.2 Cł	sentativeness: Selection Bias of Biomarker Population heck selection bias in terms of key clinical variables, between full population and BEP heck whether the clinical outcome in BEP is comparable to the full population	4
3		rker property and its association to clinical variables comarker property and relationship to clinical variable	7
4	4.1 Es 4.2 Su	rker subgroup analysis stimations within each subgroup ubgroup analysis	ę
	4.3 Cl	heck whether biomarker subgroup is confounded with key clinical variables	1

1 The dataset

The dataset have 368 entries. In which 223 are in biomarker evaluable population (BEP).

Endpoint of interest: Lab_ontrtBiomarker: KRAS.mutantBiomarker type: categorical

2 Representativeness: Selection Bias of Biomarker Population

In this section, we are trying to answer the question: Are biomarker evaluable population representative of the full population population?

Key baseline demographics and prognostic characteristics (including stratification variables and any variables with known prognostic effect) and efficacy outcomes should be summarized by treatment groups and compared between biomarker evaluable population (BEP) and the full population. These analyses are conducted to investigate any potential selection bias associated with the availability of the biomarker (e.g. we may not get enough tissue for patients whose tumor size is small. Therefore they may be excluded from BEP).

The key clinical biomarkers considered are:

```
clinical.vars.class
```

```
## Sex Age
## "categorical" "numeric"
```


2.1 Check selection bias in terms of key clinical variables, between full population and BEP

	All	BEP
Sex		
Total	368	223
NA's	0	0
\mathbf{F}	184 (50%)	111 (49.78%)
\mathbf{M}	184 (50%)	112 (50.22%)
Age	, ,	,
N	368	223
Mean	54.03	54.27
Median	54	54
Min-Max	3089	3389
NA's	0	0

2.2 Check whether the clinical outcome in BEP is comparable to the full population

The following plot compares continuous outcome in BEP vs. the full population. The response category distribution is plotted for each arm. The BEP bars are expected to be comparable to those in full population.

Full population vs. BEP: Lab_ontrt



2.3 Examine whether the prognostic/null trend of key clinical variables holds in BEP

The following forest plot can be used to examine whether any of the key prognostic clinical variables still show prognostic trend in BEP:

Stratification is not supported for continuous outcome

```
## Stratification is not supported for continuous outcome
## Stratification is not supported for continuous outcome
## Stratification is not supported for continuous outcome
```


Within arm, Compare BEP vs. All Lab_ontrt Unadjusted, unstratified analysis

Subgroup	Group	Mean	delta	(CI)	raw P	
ITT Sex(F)	No	22.24				
	Yes	22.11	-0.13	(-1.6 - 1.34)	0.86	
BEP Sex(F)	No	21.99				
	Yes	22.85	0.85	(-0.95 - 2.65)	0.35	
ITT Sex(M)	No	22.11				
	Yes	22.24	0.13	(-1.34 - 1.6)	0.86	
BEP Sex(M)	No	22.85				
	Yes	21.99	-0.85	(-2.65 - 0.95)	0.35	
ITT Age(>=50%, 54)	Less	22.45				
	Greater	21.92	-0.53	(-2 - 0.94)	0.48	
BEP Age(>=50%, 54)	Less	22.25				
	Greater	22.58	0.33	(-1.47 - 2.14)	0.72	
ITT Age(<50%, 54)	Greater	21.92				
	Less	22.45	0.53	(-0.94 - 2)	0.48	
BEP Age(<50%, 54)	Greater	22.58				
	Less	22.25	-0.33	(-2.14 - 1.47)	0.72	
						-2.5 -2 -1.5 -1 -0.5 0 0.5 1 1.5 2 2.5 delta

Full population

Μ


BEP



[1] ""

Sex

F




3 Biomarker property and its association to clinical variables

Relationship between the biomarker and key demographic and prognostic variables should also be investigated using bivariate plots. Prognostic property of the biomarker should also be assessed, by estimates of the clinical efficacy in the control arm.

3.1 Biomarker property and relationship to clinical variable

The following results show single variate plot for biomaker and bi-variate plots to investigate biomarker-clinical variable relationship.




4 Biomarker subgroup analysis

4.1 Estimations within each subgroup

The following figures investigate whether the biomarker shows a within-arm effect (e.g. patients in one biomarker subgroup tend to have better clinical outcome):

```
if(bm.class=="numeric"){
if(!is.null(numerical.finalcut)) levs <- paste0(c(">=","<"),numerical.finalcut)</pre>
if(is.null(numerical.finalcut)) {
  nm <- quantile(input.bep[[bm]], percentile.finalcut, 2) # default quantile type in forest plot functio
 numerical.finalcut <- round(nm,2) # default rounding decimal in forest plots
 levs <- paste0(c(">=","<"),percentile.finalcut*100,"%")</pre>
bm2 <- paste0(bm,"_Dx")</pre>
input[[bm2]] <- ifelse(input[[bm]] >= numerical.finalcut, levs[1],levs[2])
input[[bm2]]<- factor(input[[bm2]], levels=levs) # ">=" as Dx+
if(bm.class=="categorical") {
 bm2 \leftarrow bm
  levs <- unique(input[[bm2]])</pre>
res.2group <- PlotTabForestBiomarker(data=input,
                                   outcome.class=outcome.class,
                                   outcome.var=outcome.var,
                                   trt=trt,
                                   var=bm2,
                                   var.class="categorical",
                                   greater=TRUE, less=TRUE,
                                   show.itt=TRUE, show.bep=TRUE,
                                   covariate=covariate, strata=strata)
## Stratification is not supported for continuous outcome
## Some NAs in var column, will define the non NA entries as BEP
## only 1 arm; show.itt is set to FALSE
## only 1 arm; show.bep is set to FALSE
```

Within-arm Effect of Biomarker Lab_ontrt, KRAS.mutant Unadjusted, unstratified analysis



The forest plots above show within-arm mean difference (delta) across biomarker subgroups. For a given arm, if the delta is not all around 0, it indicates that within this arm the biomarker has an association to the clinical outcome.


4.2 Subgroup analysis

The following figure show distribution of the continuous endpoint within the biomarker subgroups:

```
input.bep <- input[which(input[[BEP]]==BEP.indicator),]

BoxPlot(obj=input.bep, form=as.formula(paste(outcome.var,"~",bm)),
    # XaxisTab=list(font=2, col="darkblue", cex=1.25),
    Title=list(main="BEP: biomarker subgroups"),
    mar=c(5,8,5,1))</pre>
```





4.3 Check whether biomarker subgroup is confounded with key clinical variables

The following table checks whether the biomarker subgroup is confounded with clinical variables. Here we check whether the clinical variable distribution is comparable in biomarker subgroups.

```
kable(
SummaryVars(data=input.bep,trt=trt, subgroup=bm2, var=clinical.vars,
var.class=clinical.vars.class, subgroup.indicator=levs[i],compare.subgroup=TRUE)
)
```

	$KRAS.mutant_Mutant$	KRAS.mutant_Wild Type
Sex		
Total	61	162
NA's	0	0
F	35 (57.38%)	76 (46.91%)
M	26 (42.62%)	86 (53.09%)
Age	, ,	· · ·
N	61	162
Mean	54.92	54.03
Median	54	53
Min-Max	3489	3382
NA's	0	0